What does Xpressbiox do?
XpressBioX specializes in the development and production of innovative biopharmaceuticals. The company focuses on harnessing advanced biotechnology to create solutions for unmet medical needs. With a commitment to quality and efficiency, XpressBioX aims to improve patient outcomes through its cutting-edge products.
- Signals
-
ProfitableProfitable € 75K
The company reported a positive net result in the latest financial year.
Strong equityStrong equity € 8.90MStrong equity provides a buffer against setbacks.
Low riskLow risk 99.8%Good solvency (> 30%) points to long-term financial stability.
Good liquidityGood liquidity 7.70A healthy current ratio (≥ 1.5): enough current assets to cover short-term debt.
Positive cashflowPositive cashflow € 182KPositive operating cash flow in the latest financial year.
Positive EBITDAPositive EBITDA € 185KPositive EBITDA: operating activities are profitable.
Financial ratios
|
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2025
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2024
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2023
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2022
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
|---|---|---|---|---|
|
€
198K
|
€
198K
|
|
|
|
|
€
185K
|
€
179K
|
€
177K
|
€
-71K
|
|
|
€
75K
|
€
-51K
|
€
-61K
|
€
-170K
|
|
|
€
8.90M
|
€
8.83M
|
€
8.88M
|
€
8.94M
|
|
|
99.83%
|
99.05%
|
42.82%
|
45.80%
|
|
|
€
15K
|
€
85K
|
€
11.86M
|
€
10.58M
|
|
|
-
|
-
|
€
25K
|
€
930K
|
Publications 14
All publications- Assemblee Generale 28/01/2025
- Demissions, Nominations 25/04/2024
- Statuts (Traduction, Coordination, Autres Modifications, ) - Demissions, Nominations 04/04/2023
- Demissions, Nominations 30/12/2022
- Statuts (Traduction, Coordination, Autres Modifications, ) - Capital, Actions - Demissions, Nominations 09/12/2022
Frequently asked questions
Answers to the most common questions about Xpressbiox, based on official government data and the filed annual accounts.
What is the VAT number of Xpressbiox?
The VAT number of Xpressbiox is BE0770.527.814.
When was Xpressbiox established?
Xpressbiox was founded in 30-06-2021.
What is the official address of Xpressbiox?
The official address of Xpressbiox is Avenue Du Parc Industriel 89 Herstal 4041.
What is the legal form of Xpressbiox?
The juridical form of Xpressbiox is Private limited company (BV/SRL).
What is the annual revenue of Xpressbiox?
The revenue of Xpressbiox for the 2025 financial year was €198,000.
What does Xpressbiox do?
XpressBioX specializes in the development and production of innovative biopharmaceuticals. The company focuses on harnessing advanced biotechnology to create solutions for unmet medical needs. With a commitment to quality and efficiency, XpressBioX aims to improve patient outcomes through its cutting-edge products.
Is Xpressbiox a reliable company?
Xpressbiox is a registered Rechtspersoon with company number 0770.527.814 and can be verified through the official CBE database.
What is the credit limit of Xpressbiox?
The estimated credit limit of Xpressbiox is €809,613.
Is Xpressbiox still active?
Xpressbiox currently has the status "Normal situation" and is active.